Roche details its AI-driven pipeline gains and cautious token spending, while shelving Carmot's acmopatide after a $277M impairment charge.
Roche has offered some insight into how it is using AI, from drug discovery to token use.
AI has already contributed to “a significant increase …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AstraZeneca CEO Pascal Soriot says AI could boost late-stage trial success and speed FDA filings, following Wainua's surprise…
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
Drug companies are betting AI can fix the slow, expensive process of testing new drugs in humans.
In this week’s edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure’s $7 billion…
Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if…
AI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readout
